i2o Therapeutics, Inc

Obsidian Therapeutics Inc, based in Cambridge, MA, is at the forefront of precision cell and gene therapy, utilizing its proprietary cytoDRIVE platform to engineer regulated therapeutic proteins. The company is dedicated to pioneering the next generation of engineered therapeutics to address critical patient needs. With a focus on innovative solutions, Obsidian is advancing its lead clinical program, OBX115, an engineered TIL cell therapy targeting advanced melanoma. The company’s commitment to collaboration and urgency drives its mission to improve patient outcomes through cutting-edge science and technology. Generated from the website

Click Therapeutics, based in Boston, MA, is pioneering the field of digital medicine by creating patient-centric digital treatments that integrate neuroscience with software technology. Their innovative platform develops, validates, and commercializes software as prescription medical treatments aimed at addressing unmet medical needs across various health conditions. The company's Software-Enhanced Drugs (Click SE) combine pharmacotherapy with digital therapeutics to provide enhanced clinical benefits to patients. By employing a multimodal approach, Click Therapeutics targets diseases from multiple angles, leveraging scientifically proven therapies alongside proprietary neuromodulatory mechanisms for clinically significant interventions. Generated from the website

Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare's team has uncovered switch sites,' druggable regions that are key targets for transcription factor regulation to address mutations that cause disease. Our drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation.